
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Pegfilgrastim
Therapeutic Area : Hematology
Study Phase : Approved FDF
Sponsor : JAMP PHARMA
Deal Size : Inapplicable
Deal Type : Inapplicable
Kashiv and JAMP Launch PEXEGRA and FILRA Biosimilars in Canada
Details : Pexegra (pegfilgrastim) biosimilar is a leukocyte growth factor indicated for the treatment of febrile neutropenia.
Product Name : Pexegra
Product Type : Protein
Upfront Cash : Inapplicable
September 24, 2025
Lead Product(s) : Pegfilgrastim
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Sponsor : JAMP PHARMA
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Omalizumab
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Cristalia Produtos Quimicos Farma. Ltda
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Kashiv and CRISTÁLIA Enter into Licensing and Supply Agreement in Latin America
Details : The agreement aims for the commercialization of ADL-018 (Omalizumab), a proposed biosimilar to Xolair, in Latin America (LATAM).
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
September 11, 2025
Lead Product(s) : Omalizumab
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Cristalia Produtos Quimicos Farma. Ltda
Deal Size : Undisclosed
Deal Type : Licensing Agreement

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Omalizumab
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : MS Pharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Kashiv and MS Pharma Enter into MENA License and Supply Agreement for ADL-018
Details : MS Pharma will be responsible for the licensing, distribution, and commercialization of ADL-018, biosimilar candidate to Xolair (omalizumab), in the MENA region.
Product Name : ADL-018
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
August 05, 2025
Lead Product(s) : Omalizumab
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : MS Pharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : KSHN001034
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Eric Solutions | Clinexcel Research
Deal Size : Inapplicable
Deal Type : Inapplicable
KSHN001034 MAD Safety, Tolerability and PK In Postmenopausal Females
Details : KSHN001034 is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of unspecified medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 29, 2025
Lead Product(s) : KSHN001034
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Eric Solutions | Clinexcel Research
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : ADL-018
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ADL-018 is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Chronic Urticaria.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
April 15, 2025
Lead Product(s) : ADL-018
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Abatacept
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Abatacept is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Arthritis, Rheumatoid.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
April 15, 2025
Lead Product(s) : Abatacept
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : TPI-120
Therapeutic Area : Hematology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Open Label Randomized Comparative Crossover Pharmacokinetic and Immunogenicity Study
Details : TPI-120 is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Febrile Neutropenia.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
April 09, 2025
Lead Product(s) : TPI-120
Therapeutic Area : Hematology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Omalizumab
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : GoldenTree
Deal Size : Undisclosed
Deal Type : Financing
Kashiv BioSciences Secures $150 Million Debt Financing from GoldenTree Asset Management
Details : The financing aims to advance the clinical development of ADL-018 (omalizumab), which is being evaluated for the treatment of asthma.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
April 07, 2025
Lead Product(s) : Omalizumab
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : GoldenTree
Deal Size : Undisclosed
Deal Type : Financing

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Omalizumab
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
UK MHRA Accepts MAA for ADL-018, A Proposed Biosimilar Of Xolair®
Details : ADL-018 (omalizumab) is an antibody inhibiting IgE binding. It is being evaluated to treat chronic spontaneous urticaria & moderate to severe persistent asthma.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
March 26, 2025
Lead Product(s) : Omalizumab
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Abatacept
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Kashiv’s Phase 1 Abatacept Biosimilar KSHB002 Shows Success
Details : KSHB002 (abatacept) is a biosimilar of orencia, a selective T cell costimulation modulator indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA).
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
January 28, 2025
Lead Product(s) : Abatacept
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
